Targeting JAK-STAT signal transduction in IBD

Christoffer Soendergaard; Fredrik Holmberg Bergenheim; Jakob Tveiten Bjerrum; Ole Haagen Nielsen

doi:10.1016/j.pharmthera.2018.07.003

Targeting JAK-STAT signal transduction in IBD

Christoffer Soendergaard, Fredrik Holmberg Bergenheim, Jakob Tveiten Bjerrum, Ole Haagen Nielsen

Department of Clinical Medicine

37 Citations (Scopus)

Abstract

An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.

Original language	English
Journal	Pharmacology & Therapeutics
Volume	192
Pages (from-to)	100-111
ISSN	0163-7258
DOIs	https://doi.org/10.1016/j.pharmthera.2018.07.003
Publication status	Published - Dec 2018

Access to Document

10.1016/j.pharmthera.2018.07.003

Cite this

@article{a93a4ab66d1b4a099755af50aa85a3bd,

title = "Targeting JAK-STAT signal transduction in IBD",

abstract = "An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.",

author = "Christoffer Soendergaard and Bergenheim, {Fredrik Holmberg} and Bjerrum, {Jakob Tveiten} and Nielsen, {Ole Haagen}",

year = "2018",

month = dec,

doi = "10.1016/j.pharmthera.2018.07.003",

language = "English",

volume = "192",

pages = "100--111",

journal = "Pharmacology & Therapeutics",

issn = "0163-7258",

publisher = "Elsevier",

}

TY - JOUR

T1 - Targeting JAK-STAT signal transduction in IBD

AU - Soendergaard, Christoffer

AU - Bergenheim, Fredrik Holmberg

AU - Bjerrum, Jakob Tveiten

AU - Nielsen, Ole Haagen

PY - 2018/12

Y1 - 2018/12

N2 - An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.

AB - An unmet medical need exists for novel targeted therapies for inflammatory bowel disease (IBD) as many patients experience inadequate responses to antibody-based biologics. An oral drug formulation with reduced production costs and redundancy for healthcare staff to administer therapy ideally should result in diminished healthcare expenses and improved patient compliance. A new drug class of small molecules, the Janus kinase (JAK) inhibitors (jakinibs), fulfills these criteria and has recently shown efficacy in IBD. Here we provide an overview of the mode of action of jakinibs and provide a comprehensive overview of existing clinical studies. Convincing clinical data show that a complex cytokine-driven inflammation can efficiently be modulated by therapeutic inhibition of the JAK proteins.

U2 - 10.1016/j.pharmthera.2018.07.003

DO - 10.1016/j.pharmthera.2018.07.003

M3 - Journal article

C2 - 30048708

SN - 0163-7258

VL - 192

SP - 100

EP - 111

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

ER -

Targeting JAK-STAT signal transduction in IBD

Abstract

Access to Document

Fingerprint

Cite this